☆ 4.8 Article

The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis

ONCOGENE (2023)

Related references

Note: Only part of the references are listed.

Article Urology & Nephrology

Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial

Yasmin Abu-Ghanem et al.

Summary: The post hoc analysis of the SURTIME trial data showed that patients in the deferred nephrectomy arm had a higher percentage of receiving sunitinib compared to the immediate nephrectomy arm, and they also had a more profound reduction of target lesions. Starting with systemic therapy may impair the administration, onset, and duration of sunitinib in comparison to the deferred approach, potentially leading to early and more profound disease control.

BJU INTERNATIONAL (2022)

Add to Collection

Article Oncology

A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression

Wentao Liu et al.

Summary: Our study identified that NFAT1, when overexpressed in RCC, was associated with poor prognosis and could enhance tumor growth by increasing PD-L1 expression. Additionally, NFAT1 was found to be stabilized in sunitinib-resistant RCC through hyperactivation of the PI3K/AKT/GSK-3 beta signaling pathway. The downregulation of FBW7, which promotes NFAT1 degradation, was induced by FOXA1 and SETD2 in sunitinib-resistant RCC, contributing to immune response modulation. This study reveals a new role for the FBW7/NFAT1 axis in RCC response to TKIs and ICIs, suggesting NFAT1 as a potential therapeutic target for RCC treatment.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Cell Biology

Regulation of PTEN and ovarian cancer progression by an E3 ubiquitin ligase RBCK1

Guanghui Wang et al.

Summary: Ovarian cancer is a highly lethal gynecologic malignancy with a survival rate that has not improved over the past 20 years. Studies have shown that elevated expression of RBCK1 in ovarian cancer patients is associated with poor prognosis. RBCK1 promotes PTEN degradation, potentially serving as a new therapeutic target for ovarian cancer treatment.

HUMAN CELL (2022)

Add to Collection

Review Pharmacology & Pharmacy

Renal cell carcinoma therapy: Current and new drug candidates

Olivia Pontes et al.

Summary: Renal cell carcinoma is the most common and lethal tumor of the urological system, with various treatment options available including surgery and targeted therapies. However, the development of resistance and limited durable responses highlight the need for new anticancer candidates with improved selectivity and efficacy. Recent research has focused on novel natural and synthetic compounds for treating RCC.

DRUG DISCOVERY TODAY (2022)

Add to Collection

Review Oncology

Advances in Renal Cell Carcinoma Drug Resistance Models

Yien Xiang et al.

Summary: This article summarizes the established methods and applications of in vivo and in vitro RCC drug resistance models, aiming to improve understanding of resistance mechanisms, increase treatment efficacy, and provide a theoretical basis for the development and application of new drugs.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway

Wei Li et al.

Summary: Our study identified a novel YY1/HDAC2/YTHDC1/ANXA1 axis that modulates the progression and chemosensitivity of ccRCC. Low expression of YTHDC1 in ccRCC tissues is associated with poor prognosis, and YTHDC1 inhibits renal cancer cell progression by downregulating the ANXA1/MAPK pathways. Additionally, the YTHDC1/ANXA1 axis influences the sensitivity of tyrosine kinase inhibitors, and HDAC2 inhibitors can resensitize ccRCC to these inhibitors through the complex.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Chemistry, Medicinal

Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways

Yingwei Xie et al.

Summary: This study investigated the molecular mechanisms of sunitinib resistance in ccRCC by constructing a drug-resistant cell-derived xenograft model. The findings highlighted the role of ubiquitinase in drug resistance and its potential as a therapeutic target and biomarker.

DRUG DESIGN DEVELOPMENT AND THERAPY (2021)

Add to Collection

Article Oncology

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts

S. Aeppli et al.

Summary: In the first-line treatment of metastatic clear cell renal cell carcinoma, experts recommended various drugs and drug combinations based on different decision criteria and parameters, with significant inter-expert variations observed. This demonstrates how data from randomized trials are implemented differently in daily practice.

ESMO OPEN (2021)

Add to Collection

Article Biology

Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma

Maeva Dufies et al.

Summary: Dufies et al. found high Plk1 expression levels in aggressive clear cell renal cell carcinoma and discovered that Plk1 is transcriptionally upregulated in a manner dependent on HIF-2. They also found that high Plk1 expression is correlated to a poor prognosis and resistance to tyrosine kinase inhibitor against VEGF receptor, suggesting a critical role for hypoxia/HIF-2-induced Plk1 in disease progression.

COMMUNICATIONS BIOLOGY (2021)

Add to Collection

Article Oncology

Regulation of ERα Stability and Estrogen Signaling in Breast Cancer by HOIL-1

Jianing Ding et al.

Summary: ERα plays a crucial role in breast tumor development, and HOIL-1 is involved in modulating ERα signaling, showing good prognosis in ERα positive breast cancer but poor outcome in patients receiving endocrine therapy.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2

Yongzhen Mo et al.

Summary: Our study revealed that a novel circRNA, circRNF13, plays a crucial role in NPC development through the circRNF13-SUMO2-GLUT1 axis. CircRNF13 inhibits NPC proliferation and metastasis by activating SUMO2 and regulating the AMPK-mTOR pathway to inhibit glycolysis. This research provides a theoretical basis for further understanding NPC pathogenesis and developing targeted therapies.

MOLECULAR CANCER (2021)

Add to Collection

Article Chemistry, Multidisciplinary

RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway

Wei Xiong et al.

Summary: The study reveals that upregulated RRM2 in sunitinib-resistant RCC promotes resistance to TKIs, but the exact mechanism remains unclear. Additionally, RRM2 also impacts anti-tumor immune responses, and silencing RRM2 can enhance the efficacy of PD-1 blockade in renal cancer.

ADVANCED SCIENCE (2021)

Add to Collection

Article Oncology

Prognostic Impact of MITD1 and Associates With Immune Infiltration in Kidney Renal Clear Cell Carcinoma

Chujie Chen et al.

Summary: The study found that MITD1 expression is significantly increased in KIRC tissues and is associated with worse overall survival and disease free survival rates in KIRC patients. There is also a significant correlation between MITD1 expression and the abundance of CD8+ T cells. Functional enrichment analyses revealed that immune response and cytokine-cytokine receptor are critical signaling pathways associated with MITD1 in KIRC.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2021)

Add to Collection

Article Cell Biology

LINC00160 mediates sunitinib resistance in renal cell carcinoma via SAA1 that is implicated in STAT3 activation and compound transportation

Gong Cheng et al.

Aging-US (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Identifying chromosomal subpopulations based on their recombination histories advances the study of the genetic basis of phenotypic traits

Carlos Ruiz-Arenas et al.

GENOME RESEARCH (2020)

Add to Collection

Article Oncology

MTSS1 suppresses mammary tumor-initiating cells by enhancing RBCK1-mediated p65 ubiquitination

Min Cong et al.

NATURE CANCER (2020)

Add to Collection

Article Multidisciplinary Sciences

Ubiquitin-dependent chloroplast-associated protein degradation in plants

Qihua Ling et al.

SCIENCE (2019)

Add to Collection

Article Cell Biology

RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma

Sifan Yu et al.

CELL DEATH & DISEASE (2019)

Add to Collection

Article Biochemistry & Molecular Biology

ANKRD9 is a metabolically-controlled regulator of IMPDH2 abundance and macro-assembly

Dawn Hayward et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2019)

Add to Collection

Article Multidisciplinary Sciences

The E3 ligase HOIL-1 catalyses ester bond formation between ubiquitin and components of the Myddosome in mammalian cells

Ian R. Kelsall et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Add to Collection

Article Medicine, Research & Experimental

RBCK1 contributes to chemoresistance and sternness in colorectal cancer (CRC)

Min-Li Liu et al.

BIOMEDICINE & PHARMACOTHERAPY (2019)

Add to Collection

Review Pathology

Protein Degradation and the Pathologic Basis of Disease

John Hanna et al.

AMERICAN JOURNAL OF PATHOLOGY (2019)

Add to Collection

Review Medicine, General & Internal

Novel Insights Into E3 Ubiquitin Ligase in Cancer Chemoresistance

Li Yang et al.

AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2018)

Add to Collection

Review Oncology

Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma

Michael B. Atkins et al.

CANCER TREATMENT REVIEWS (2018)

Add to Collection

Review Pharmacology & Pharmacy

Post-translational modifications of transporters

Lindsay C. Czuba et al.

PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection

Review Plant Sciences

Protein Language: Post-Translational Modifications Talking to Each Other

Lam Dai Vu et al.

TRENDS IN PLANT SCIENCE (2018)

Add to Collection

Review Urology & Nephrology

Metabolic reprogramming in clear cell renal cell carcinoma

Hiromi I. Wettersten et al.

NATURE REVIEWS NEPHROLOGY (2017)

Add to Collection

Review Pharmacology & Pharmacy

Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas

Robert Roskoski

PHARMACOLOGICAL RESEARCH (2017)

Add to Collection

Review Urology & Nephrology

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence

Mimma Rizzo et al.

THERAPEUTIC ADVANCES IN UROLOGY (2017)

Add to Collection

Review Transplantation

Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease

Prathibha R. Gajjala et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)

Add to Collection

Review Cell Biology

Knowing when to but and run: mechanisms that control cytokinetic abscission

Monica Agromayor et al.

TRENDS IN CELL BIOLOGY (2013)

Add to Collection

Review Cell Biology

Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase

Yi Sun et al.

PROTEIN & CELL (2013)

Add to Collection

Article Cell Biology

MITD1 is recruited to midbodies by ESCRT-III and participates in cytokinesis

Seongju Lee et al.

MOLECULAR BIOLOGY OF THE CELL (2012)

Add to Collection

Article Biochemistry & Molecular Biology

Solution structure of the E3 ligase HOIL-1 Ubl domain

Steven A. Beasley et al.

PROTEIN SCIENCE (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.